Logo image of MOLN

MOLECULAR PARTNERS AG -ADR (MOLN) Stock Fundamental Analysis

NASDAQ:MOLN - Nasdaq - US60853G1067 - ADR - Currency: USD

4.681  -0.23 (-4.75%)

Fundamental Rating

3

Taking everything into account, MOLN scores 3 out of 10 in our fundamental rating. MOLN was compared to 571 industry peers in the Biotechnology industry. The financial health of MOLN is average, but there are quite some concerns on its profitability. MOLN is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year MOLN has reported negative net income.
MOLN had a negative operating cash flow in the past year.
In the past 5 years MOLN reported 4 times negative net income.
In the past 5 years MOLN reported 4 times negative operating cash flow.
MOLN Yearly Net Income VS EBIT VS OCF VS FCFMOLN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M

1.2 Ratios

MOLN has a Return On Assets of -40.48%. This is comparable to the rest of the industry: MOLN outperforms 55.42% of its industry peers.
MOLN has a Return On Equity of -44.40%. This is in the better half of the industry: MOLN outperforms 68.74% of its industry peers.
Industry RankSector Rank
ROA -40.48%
ROE -44.4%
ROIC N/A
ROA(3y)-7.75%
ROA(5y)-18.26%
ROE(3y)-14.82%
ROE(5y)-34.01%
ROIC(3y)N/A
ROIC(5y)N/A
MOLN Yearly ROA, ROE, ROICMOLN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20 -20 40 -40 -60

1.3 Margins

MOLN has a better Gross Margin (67.56%) than 81.71% of its industry peers.
In the last couple of years the Gross Margin of MOLN has grown nicely.
MOLN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 67.56%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.04%
GM growth 5Y4.61%
MOLN Yearly Profit, Operating, Gross MarginsMOLN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -200 -400 -600 -800

More info and screens

6

2. Health

2.1 Basic Checks

MOLN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for MOLN has been increased compared to 1 year ago.
MOLN has more shares outstanding than it did 5 years ago.
The debt/assets ratio for MOLN has been reduced compared to a year ago.
MOLN Yearly Shares OutstandingMOLN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M
MOLN Yearly Total Debt VS Total AssetsMOLN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

2.2 Solvency

An Altman-Z score of 4.12 indicates that MOLN is not in any danger for bankruptcy at the moment.
With a decent Altman-Z score value of 4.12, MOLN is doing good in the industry, outperforming 78.33% of the companies in the same industry.
MOLN has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
MOLN has a Debt to Equity ratio of 0.01. This is comparable to the rest of the industry: MOLN outperforms 41.92% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z 4.12
ROIC/WACCN/A
WACC4.84%
MOLN Yearly LT Debt VS Equity VS FCFMOLN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100M 200M

2.3 Liquidity

A Current Ratio of 14.58 indicates that MOLN has no problem at all paying its short term obligations.
With an excellent Current ratio value of 14.58, MOLN belongs to the best of the industry, outperforming 88.45% of the companies in the same industry.
A Quick Ratio of 14.58 indicates that MOLN has no problem at all paying its short term obligations.
MOLN has a better Quick ratio (14.58) than 88.63% of its industry peers.
Industry RankSector Rank
Current Ratio 14.58
Quick Ratio 14.58
MOLN Yearly Current Assets VS Current LiabilitesMOLN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

More info and screens

3

3. Growth

3.1 Past

MOLN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 23.60%, which is quite impressive.
The Revenue for MOLN has decreased by -25.37% in the past year. This is quite bad
MOLN shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -7.43% yearly.
EPS 1Y (TTM)23.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%51.11%
Revenue 1Y (TTM)-25.37%
Revenue growth 3Y-9.01%
Revenue growth 5Y-7.43%
Sales Q2Q%-57.93%

3.2 Future

Based on estimates for the next years, MOLN will show a decrease in Earnings Per Share. The EPS will decrease by -6.33% on average per year.
Based on estimates for the next years, MOLN will show a very strong growth in Revenue. The Revenue will grow by 56.58% on average per year.
EPS Next Y17.79%
EPS Next 2Y-1.25%
EPS Next 3Y1.24%
EPS Next 5Y-6.33%
Revenue Next Year-25%
Revenue Next 2Y-33.86%
Revenue Next 3Y40.1%
Revenue Next 5Y56.58%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
MOLN Yearly Revenue VS EstimatesMOLN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M 400M
MOLN Yearly EPS VS EstimatesMOLN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 1 -1 2 -2 3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MOLN. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MOLN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MOLN Price Earnings VS Forward Price EarningsMOLN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MOLN Per share dataMOLN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-1.25%
EPS Next 3Y1.24%

More info and screens

0

5. Dividend

5.1 Amount

MOLN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MOLECULAR PARTNERS AG -ADR

NASDAQ:MOLN (2/21/2025, 8:00:01 PM)

4.681

-0.23 (-4.75%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-26 2024-08-26/amc
Earnings (Next)03-06 2025-03-06/amc
Inst Owners45.23%
Inst Owner Change-99.97%
Ins Owners4.04%
Ins Owner ChangeN/A
Market Cap172.56M
Analysts82.22
Price Target12.04 (157.21%)
Short Float %0.16%
Short Ratio3.54
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-5.76%
PT rev (3m)19.8%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)6.82%
EPS NY rev (3m)16.09%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-29.41%
Revenue NY rev (3m)-29.41%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 14.93
P/FCF N/A
P/OCF N/A
P/B 1
P/tB 1
EV/EBITDA N/A
EPS(TTM)-2.07
EYN/A
EPS(NY)-2.06
Fwd EYN/A
FCF(TTM)-1.89
FCFYN/A
OCF(TTM)-1.87
OCFYN/A
SpS0.31
BVpS4.69
TBVpS4.68
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -40.48%
ROE -44.4%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 67.56%
FCFM N/A
ROA(3y)-7.75%
ROA(5y)-18.26%
ROE(3y)-14.82%
ROE(5y)-34.01%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.04%
GM growth 5Y4.61%
F-Score4
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 32.89%
Cap/Sales 7.63%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 14.58
Quick Ratio 14.58
Altman-Z 4.12
F-Score4
WACC4.84%
ROIC/WACCN/A
Cap/Depr(3y)47.89%
Cap/Depr(5y)55.49%
Cap/Sales(3y)8.54%
Cap/Sales(5y)10.56%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)23.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%51.11%
EPS Next Y17.79%
EPS Next 2Y-1.25%
EPS Next 3Y1.24%
EPS Next 5Y-6.33%
Revenue 1Y (TTM)-25.37%
Revenue growth 3Y-9.01%
Revenue growth 5Y-7.43%
Sales Q2Q%-57.93%
Revenue Next Year-25%
Revenue Next 2Y-33.86%
Revenue Next 3Y40.1%
Revenue Next 5Y56.58%
EBIT growth 1Y16.52%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year35.26%
EBIT Next 3Y12.01%
EBIT Next 5YN/A
FCF growth 1Y-156.41%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-155.03%
OCF growth 3YN/A
OCF growth 5YN/A